期刊文献+

5年间检出鲍曼不动杆菌及耐药性变迁的分析 被引量:2

The variations of drug resistance of Acinetobacter baumanii detected in the last five years.
下载PDF
导出
摘要 目的 了解深圳市第二人民医院2001~2005年检出鲍曼不动杆菌的标本来源、分布及耐药变迁趋势,为有效防控制感染、指导临床合理用药提供依据。方法 回顾性调查和统计该院2001年1月~2005年12月临床送栓标本中鲍曼不动杆菌栓出情况并分析。结果 鲍曼不动杆菌栓出由2001年全年12株上升至2005年全年63株。5年中发现一株全耐株;高耐株、泛耐株共占15.6%。对鲍曼不动杆菌最为敏感的药物是亚胺培南。临床分离的鲍曼不动杆菌主要来源于痰标本占60.1%,其主要来自呼吸科。结论 鲍曼不动杆菌的感染率和耐药率正在不断上升.应重视防治。 Objective To understand the variations of tendency of drug - resistance, the origin and the distributing of Acinetobacter baumannii and provide basis for selection of chnical drugs. Methods The data concerning Acinetobacter baumannii infection in our hospital in 2001 - 2005 were retrospectively and statistically analyzed. Results The total strains of Acinetobacter baumannii isolated from this hospital was increased from 12 strains in 2001 to 63 strains in 2005 , and a panresistant strain was detected in the last five years. High drug- resistance and pan- resistant strains were accounted for 15.6%. Acinetobacter baumannii was most sensitive to imipenem. 60% of Acinetobacter baumannii were isolated from sputum specimens. Conclusion The infection rate of Acinetobacter baumannii is increasing and measures be adopted for control Acinetobacter baumannii infection in hospital.
作者 高霞
出处 《中国热带医学》 CAS 2006年第9期1665-1666,共2页 China Tropical Medicine
关键词 鲍曼不动杆菌 感染 耐药性 Acinetobacter baumannii Infection Drug resistance
  • 相关文献

参考文献5

二级参考文献36

  • 1糜祖煌,黄支密,秦玲.鲍氏不动杆菌耐药性和氨基糖苷类修饰酶、β-内酰胺酶基因研究[J].中华医院感染学杂志,2004,14(9):968-971. 被引量:136
  • 2[1]Brisse S, Milatovic D, Fluit A C. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp using automated ribotyping [J]. J Clin Microbiol, 2000,38 (10): 3636
  • 3[2]Afzal-Shah M, Livermore D M. Worldwide emergence of carbapenem-resistant Acinetobacter spp[J] . J Antimicrob Chemother , 1998,41:576
  • 4[3]Robert E W. Resistant mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria [J]. Clin Infect Dis, 1998,27(Suppll): S93
  • 5[4]Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain [J]. Antimicrob Agents Chemother, 2000,44(6):1556
  • 6[5]Fernandez-viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumanniiwith intraventricular colistim sulfomethate sodium[J].Clin Infect Dis, 1999,28(4) :916
  • 7Sengupta S, Kumar P, Ciraj AM, et al. Acinetobacter baumannii-An emerging nosocomial pathogen in the bums unit Manipal, india. Bums,2001, 27(2):140-144.
  • 8Vahaboglu H, Ozturk R, Aygun G , et al. Widespread detection of PER-1-type extended-spectrum b-lactarnases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide muhicenter stndy. Antimicrob Agents Chemother 1997 ; 41 (10) : 2265-2269.
  • 9Poirel L, Menuteau O, Agoli N, et al. Outbreak of extended-spectrum b-lactmase VEB-1 producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003 ; 41 ( 8 ) : 3542-3547.
  • 10Danes C, Navia MM, Ruiz J, etal. Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Svn 2190 ( Am-pC inhibitor) on the MICs of different beta-lactam antibiotics. J Antimicrob Chemother., 2002 Aug; 50(2) : 261-264.

共引文献565

同被引文献4

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部